West Pharmaceutical Services, Inc. (WST) fundamentals from SEC filings — revenue $3.1B, net margin 16.1%, diluted EPS $6.79 in FY2025. Revenue, margins, EPS and free cash flow, year by year.
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Net income | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| Net margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Free cash flow | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
Figures are as reported to the SEC (EDGAR companyfacts), in the filer's own fiscal years.
Sign in to PortfolioX for the full analysis — ten years of history, segment and geographic breakdowns, valuation multiples, analyst estimates and filings. · PortfolioX home